QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Levien, T. L Search for Related Content PubMed PubMed Citation Articles by Levien, T. L

DRUG INFORMATION ROUNDS

Phosphodiesterase Inhibitors in Raynaud's Phenomenon

Drug Information Pharmacist and Clinical Assistant Professor, Pharmacotherapy Department, College of Pharmacy, Washington State University Spokane, PO Box 1495, Spokane, WA 99210-1495, fax 509/358-7744, Levient{at}wsu.edu

Reprints: Dr. Levien

OBJECTIVE: To evaluate the efficacy of the phosphodiesterase type 5 (PDE5) inhibitors in the treatment of Raynaud's phenomenon.

DATA SOURCES: Searches of MEDLINE (1966-March 2006) and Web of Science (1980-March 2006) were conducted; search terms were sildenafil, tadalafil, vardenafil, phosphodiesterase, and Raynaud. Studies and case reports published in English were retrieved. Additional references were identified in bibliographic reviews.

DATA SYNTHESIS: Several small studies and a number of case reports have described the use of PDE5 inhibitors in patients with either primary or secondary Raynaud's phenomenon. The data from the best designed study show a reduced attack frequency and duration, reduced Raynaud Condition Score, and increased capillary blood flow in patients with secondary Raynaud's phenomenon.

CONCLUSIONS: Available evidence suggests that sildenafil may be associated with improved microcirculation, symptomatic relief, and ulcer healing in patients with secondary Raynaud's phenomenon. Limited information suggests similar effects with tadalafil and vardenafil. Improved blood flow and clinical improvements have also been observed in some patients with primary Raynaud's phenomenon treated with PDE5 inhibitors; however, studies have yielded conflicting results.

Key Words: Raynaud's phenomenon, sildenafil, tadalafil, vardenafil

Published Online, July 11, 2006. www.theannals.com, DOI 10.1345/aph.1H005

This article has been cited by other articles:

				A. L. Burnett Molecular Pharmacotherapeutic Targeting of PDE5 for Preservation of Penile Health J Androl, January 1, 2008; 29(1): 3 - 14. [Abstract] [Full Text] [PDF]

				M. Colakoglu, V. Cobankara, and T. Akpolat Effect of Clonazepam on Raynaud's Phenomenon and Fingertip Ulcers in Scleroderma Ann. Pharmacother., September 1, 2007; 41(9): 1544 - 1547. [Abstract] [Full Text] [PDF]